

## Press Release

Ishaan Bio Private Limited

September 07, 2018

### Rating Assigned



<b>Total Bank Facilities Rated*</b>	Rs. 9.05 Cr.
<b>Long Term Rating</b>	ACUITE BB+ / Outlook: Stable
<b>Short Term Rating</b>	ACUITE A4+

\* Refer Annexure for details

### Rating Rationale

Acuite has assigned long-term rating of '**ACUITE BB+**' (read as **ACUITE BB plus**) and short term rating of '**ACUITE A4+**' (read as **ACUITE A four plus**) to the Rs. 9.05 crore bank facilities of Ishaan Bio Private Limited (IBPL). The outlook is '**Stable**'.

The Gujarat-based, IBPL was incorporated in 2007 by Mr. Dipal Palkhiwala and Ms. Ishita Palkhiwala. IBPL is engaged in manufacture, supply and research of various Bio-products. The bio-products includes various products that are used in different industries such as beverage, leather, textile, animal feed, agriculture, paper among others. The company has R&D setup with pilot plant and application lab to research, develop and produce biotech solutions. It has in-house Quality Control and Quality Assurance labs. It is accredited with certificates of ISO 9001, ISO 22000 to name a few.

### Analytical Approach

Acuite has considered the standalone business and financial risk profiles of Ishaan Bio Private Limited to arrive at the rating.

### Key Rating Drivers

#### Strengths

- Established presence and experienced management in the industry**

The company is engaged in manufacturing of enzymes, proteins, carbohydrates and fibres. The main promoter, Mr. Dipal Palkhiwala was earlier associated with biotech company for more than two decades which is engaged in similar line of business. Established position and experienced management has helped the company to acquire reputed customers.

- Moderate financial risk profile**

The financial risk profile is moderate marked by adjusted tangible net worth at Rs.6.36 crore as on 31 March, 2018 as against Rs.4.70 crore in the previous year. IBPL's gearing stood moderate at 1.46 times as on 31 March, 2018 as compared to 1.51 times in the previous year. The company has comfortable coverage ratio for the period under study and stood at 3.71 times in FY2018 as compared to 2.15 times in FY2017. ROCE stood healthy at 22.71 percent in FY2018 as compared to 19.39 percent in FY2017. The total outside liabilities to tangible net worth stood at 2.26 times as on 31 March, 2018 as against 2.50 times in the previous year.

- Comfortable working capital management**

The operations of IBPL have remained comfortable as the Gross Current Asset (GCA) days stood at 169 in FY2018 as against 194 days in FY2017. The company has an inventory holding period of 39 days in FY2018 as against 52 days in the previous year and collection period of 100 days in FY2018, an improvement from 116 days in FY2017.

#### Weaknesses

• **Moderate scale of operation**

The operating income of the company stood at Rs.34.76 crore in FY2018 compared to Rs.23.76 crore in FY2017 and Rs.15.89 in FY2016. Acuite believes that scaling up of operations while maintaining the company's profitability will remain a key rating sensitivity.

• **Susceptibility to regulatory and compliance-related issues**

The company remains susceptible to changes in regulations related to food and drug safety norms. Any non-compliance could lead to product recall, discontinuation of business by customers, and litigation, which may adversely affect business and financial performances.

• **Margins are vulnerable to volatility in raw material prices and foreign exchange rate**

The company imports around 15-18 percent of its requirement from outside India. Hence, the margins are susceptible to volatility in foreign exchange rate in the absence of adequate hedging mechanism.

**Outlook: Stable**

Acuite believes that IBPL will maintain 'Stable' outlook over the medium term on the back of experienced management and comfortable financial risk profile. The outlook may be revised to 'Positive' in case the company registers higher-than-expected growth in revenues while improving profitability along with improved financial risk profile. Conversely, the outlook may be revised to 'Negative' in case the company registers lower-than-expected growth in revenues and profitability or in case of deterioration in the company's financial risk profile or significant elongation in working capital cycle.

**About the Rated Entity - Key Financials**

	Unit	FY18 (Actual)	FY17 (Actual)	FY16 (Actual)
Operating Income	Rs. Cr.	34.76	23.76	15.89
EBITDA	Rs. Cr.	3.56	2.14	1.26
PAT	Rs. Cr.	1.61	0.56	0.35
EBITDA Margin	(%)	10.23	8.99	7.92
PAT Margin	(%)	4.65	2.37	2.22
ROCE	(%)	22.56	18.39	26.46
Total Debt/Tangible Net Worth	Times	1.47	1.51	4.35
PBDIT/Interest	Times	3.68	2.15	2.78
Total Debt/PBDIT	Times	2.61	3.31	5.03
Gross Current Assets (Days)	Days	169	194	149

**Status of non-cooperation with previous CRA (if applicable)**

Not Applicable

**Any other information**

None

**Applicable Criteria**

- Default Recognition - <https://www.acuite.in/criteria-default.htm>
- Financial Ratios And Adjustments - <https://www.acuite.in/view-rating-criteria-20.htm>
- Manufacturing Entities - <https://www.acuite.in/view-rating-criteria-4.htm>

**Note on complexity levels of the rated instrument**

<https://www.acuite.in/criteria-complexity-levels.htm>

**Rating History (Upto last three years)**

Not Applicable

# \*Annexure – Details of instruments rated

Name of the Facilities	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. Cr.)	Ratings/Outlook
Cash Credit	Not Applicable	Not Applicable	Not Applicable	5.10	ACUITE BB+ / Stable
Term loans	Not Applicable	Not Applicable	Not Applicable	1.25	ACUITE BB+ / Stable
PC/PCFC	Not Applicable	Not Applicable	Not Applicable	2.70	ACUITE A4+

# Contacts

Analytical	Rating Desk
Aditya Gupta Head - Corporate and Infrastructure Sector Ratings Tel: 022-67141111 <a href="mailto:aditya.gupta@acuite.in">aditya.gupta@acuite.in</a>  Disha Parmar Analyst - Rating Operations Tel: 022-67141120 <a href="mailto:disha.parmar@acuiteratings.in">disha.parmar@acuiteratings.in</a>	Varsha Bist Manager - Rating Desk Tel: 022-67141160 <a href="mailto:rating.desk@acuite.in">rating.desk@acuite.in</a>

# About Acuité Ratings & Research:

Acuité Ratings & Research Limited (Erstwhile SMERA Ratings Limited) is a full-service Credit Rating Agency registered with the Securities and Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI), for Bank Loan Ratings under BASEL-II norms in the year 2012. Since then, it has assigned more than 6,000 credit ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Mumbai.

**Disclaimer:** An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Acuité ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. Acuité ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.acuite.in](http://www.acuite.in)) for the latest information on any instrument rated by Acuité.